Roche shares drop after reports of deaths of patients taking Hemlibra

ZURICH (Reuters) - Roche shares dropped on Wednesday after U.S.-based National Hemophilia Foundation said Roche's Genentech unit informed it of five deaths of patients treated with its drug Hemlibra.